Alpha Synuclein N-terminal Antibody,StressMarq Biosciences Inc.,SMC-621D

Mouse Anti-Human Alpha Synuclein N-terminal Monoclonal IgG1

Host

Mouse

Reactivity

Human, Mouse, Rat

Application

WB , IHC

Conjugate

APC, ATTO 390, ATTO 488, ATTO 594, Biotin, FITC, HRP, PerCP, RPE, Unconjugated

Platform ID

BAB025808049

StressMarq Biosciences Inc.

Headquarters

118-1537 Hillside Avenue, Victoria, British Columbia, V8T 4Y2, CANADA

Contact

Tel: +1 250-294-9065
Fax: +1 250-294-9025

Product Specifications
Scientific Background
Synonyms

Specifications

NameAlpha Synuclein N-terminal Antibody
Cat. No.SMC-621D
Accession NumberP37840
Gene ID (Entrez)6622
HostMouse
RRIDAB_3716751)
ReactivityHuman, Mouse, Rat
ConjugationAPC, ATTO 390, ATTO 488, ATTO 594, Biotin, FITC, HRP, PerCP, RPE, Unconjugated
ApplicationWB , IHC
Working DilutionsWB (1:1000), IHC (1:100); optimal dilutions for assays should be determined by the user.; optimal dilutions for assays should be determined by the user.
ClonalityMonoclonal
Concentration1mg/mL
ImmunogenAlpha synuclein aa 1-20
PurityProtein G Purified
ShippingBlue Ice or 4ºC
FormulationPBS pH7.4, 50% glycerol, 0.09% sodium azide *Storage buffer changes when conjugated
Storage-20ºC

Scientific Background

Alpha-synuclein is a presynaptic neuronal protein implicated in the pathogenesis of several neurodegenerative diseases, including Parkinson’s disease and dementia with Lewy bodies. Among its structural domains, the N-terminal region plays a pivotal role in membrane binding, conformational dynamics, and aggregation behavior. Post-translational modifications, particularly C-terminal truncations, significantly influence alpha-synuclein’s aggregation propensity and neurotoxicity (1). C-terminally truncated alpha-synuclein species are highly enriched in pathological inclusions such as Lewy bodies and Lewy neurites. These truncated forms exhibit accelerated fibrillization and enhanced prion-like propagation in cellular and animal models of Parkinson’s disease, underscoring their pathogenic relevance (1). Importantly, such truncations can alter the structural conformation of alpha-synuclein, masking epitopes commonly targeted by antibodies, including those recognizing phosphorylated serine 129 (pSer129) . This epitope masking has critical implications for research and diagnostics. Antibodies specific to pSer129 may fail to detect C-terminally truncated alpha-synuclein, potentially underestimating the burden of pathogenic species in tissue samples. Therefore, careful selection of antibodies that target the N-terminal region is essential for accurate detection and quantification of disease-relevant alpha-synuclein conformers (3). Understanding the structural and functional roles of the alpha-synuclein N-terminus is vital for elucidating disease mechanisms and developing targeted therapeutic strategies in synucleinopathies.

Synonyms

Alpha Synuclein, α-Synuclein, SNCA, alphaSYN, NACP, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, Synuclein alpha, Synuclein alpha 140, Synuclein, alpha (non A4 component of amyloid precursor), isoform NACP140, PARK1, PARK 1, PARK4, PARK 4, Parkinson disease familial 1, Parkinson disease (autosomal dominant, Lewy body) 4, SYN, SYUA_HUMAN

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.